Director Declaration
9 November 2023 15:00 BST
Director Declaration
AstraZeneca PLC (the Company) today announced that Philip Broadley, senior independent Non-Executive Director of the Company, has been appointed as Non-Executive Director and Chair designate to the Board of Lancashire Holdings Limited with effect from 8 November 2023.
This announcement is made pursuant to Listing Rule 9.6.14 R (2).
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 14 hours ago Next
- 15 hours ago CT Private Equity Trust
- 15 hours ago Kingfisher
- 15 hours ago Kingfisher
- 15 hours ago Rio Tinto